

Surgical Resection of Gastric Cancer Evidence & Issues

Carol J. Swallow
Department of Surgical Oncology
Princess Margaret and Mount Sinai Hospitals
University of Toronto



Surgical Problems in Proximal GI Cancer Management
BC Surgical Oncology Network Conference
December 3, 2005 Vancouver, BC




Surgical Resection of Gastric Cancer

- I. Technical Issues
 - RCT
 - Other
- II. Quality of Surgery
- III. Adjuvant Treatment

Case #1


50 year old healthy man
2 years of dyspepsia
OGD: antral tumour
path: invasive adenoCa









I. Technical Issues

- I. Extent of Gastrectomy
- II. Extent of Lymphadenectomy
- III. Lap vs. Open
- IV. Margins
- V. Other


French and Italian RCT Antral Ca TG vs STG: Longterm Survival




Ann Surg 1989 209:162; Ann Surg 1997 226:613




Survival after "Standard" D2 Dissection



UK postcode trial: D1 vs modified D2 Dissection Postoperative M & M Rates



UK postcode trial: D1 vs modified D2 Dissection Longterm Survival



Extent of Lymphadenectomy: Cochrane Review – D2


- more dangerous when
 - spleen/panc resected
 - surgeon inexperienced
 - studies limited by
 - learning curves, poor compliance
 - contamination
 - no PROVEN survival benefit
 - MAY benefit
 - T3+
 - Stage II & IIIa
- McCulloch et al, The Cochrane Collaboration, 2005






Extent of Lymphadenectomy: Current State of Play

- D2:
 - not harmful in expert hands
 - more nodes = better staging
 - direct survival benefit unclear
- pending:
 - Italian RCT D1 vs D2, 5 centres, n=162
 - Japan RCT D2 vs D2+, 24 centres, n=523

Degiulu, EJSO 2004; 30: 303
Sano, J Clin Oncol 2004; 22: 2767

Laparoscopic vs Open Gastrectomy: RCT






TNM Staging of Gastric Cancer

Stage 1	A	T1; N0	
	B	T1; N1 T2; N0	
Stage 2		T1; N2 T2; N1 T3; N0	
	Stage 3	A	T2; N2 T3; N1 T4; N0
		B	T3; N2
Stage 4		T4; N1, N2, N3 T1, T2, T3; N3 M1	

AJCC, 2002

National Cancer Data Base (USA) Report on Gastric Cancer (Dx 1987 - 88)



Cancer 1997; 80: 2333

Gastric Cancer Surgical RCT Pot- Pourri

Au, Inst, Date	Question	n	Answer
Doglietto, Rome, 2004	± NJT in TG	237	no diff
Inaba, Tokyo, 2004	midline vs transv	54	less pain, pneumonia, SBO in transv
Mochiki, Maebashi, 2003	J1 ± pouch	26	less caloric intake in pouch
Hori, Chiba, 2004	stapled vs HS gastroduod	187	stapled faster by 11 min, no other diff
Fiori, Rome, 2004	pall stent vs gastroent	18	shorter op time, time to food, hosp stay with stent

Case #1: Pathology Report

- poorly differentiated adenocarcinoma
- tumour penetrates through muscularis propria into adjacent greater omentum, but not through visceral peritoneum
- proximal and distal margins negative
- 0 of 12 nodes positive

WHAT STAGE IS THIS?

TNM Staging of Gastric Cancer: T Stage

- T1 Lamina propria, submucosa
- T2 Muscularis propria, subserosa
- T3 Penetrates serosa
- T4 Adjacent structures


TNM Staging of Gastric Cancer: N Stage

- N0 no regional nodes involved
- N1 1 to 6 nodes
- N2 7 to 15 nodes
- N3 > 15 nodes

TNM Staging of Gastric Cancer

Stage 1	A	T1; N0
	B	T1; N1 T2; N0
Stage 2		T1; N2 T2; N1 T3; N0
Stage 3	A	T2; N2 T3; N1 T4; N0
	B	T3; N2
Stage 4		T4; N1, N2, N3 T1, T2, T3; N3 M1

AJCC 2002, 6th edition




1997 AJCC, 5th Ed.

- N0- No regional LN metastases
- N1- Metastasis in 1-6 regional LN
- N2- Metastasis in 7-15 regional LN
- N3- Metastasis in > 15 regional LN

"...it is suggested that at least 15 regional nodes be assessed..."

The Question of Quality: Outcomes of Resection for Gastric Cancer



The Question of Quality: What is the Secret of Japan?

- younger, less CV disease
- less obese
- stage migration 2° to better N staging
- TECHNIQUE


Significant Regional Variation in Staging and Survival of Gastric Cancer- An Analysis of the SEER Database

Natalie G. Coburn, MD, MPH
Carol J. Swallow, MD, PhD
Calvin Law, MD, MPH

Proc ASCO, 2005




Defining the Study Population




Overall Results

- Ω 10,129 cases
- Ω Male: 64%
- Ω Age
 - Median: 70 years
 - Mean: 68.3±12.5 years
- Ω Median # of LN assessed: 9
- Ω Overall percentage of patients with Adequate LN assessment: 28.6%
 - Improved to 32.7% 1998-2001 (p<0.05)


Odds of Adequate LN Assessment- Year of diagnosis



Odds of Adequate LN Assessment- SEER Region



Factors Predictive of Survival- SEER Region



Cox HR of Death Final Model ($p < 0.05$ for all)

- SEER Region
- Age (vs. 60-74)
 - 18-59: HR=0.8
 - >74: HR=1.4
- Race
 - Japanese: HR=0.8
 - Other Asian: HR=0.8
 - African-American, Islanders, Other: HR=NS
- Female Gender
HR= 0.8
- Marital Status
HR=0.9
- T-Stage
HR=1.4, 2.2, 3.4
- Grade
HR= NS, 1.4, 1.4
- Radiation
 - Neoadjuvant: HR=NS
 - Adjuvant: HR=0.9
- Surgery Type (v. Distal)
 - Total: HR=0.8
 - Gastrectomy NOS: HR=1.2
 - En bloc: HR=1.12
- >15 LN assessed
HR=0.86

Gastric Cancer Lymph Node Retrieval in the Province of Ontario and at a Tertiary Care Cancer Centre

Anirban Gupta, Riad Haddad, Julinor Bacani,
Catherine O'Brien, Aaron Pollett,
Steven Gallinger and Carol Swallow

Departments of Surgical Oncology and Pathology, Mount Sinai and
Princess Margaret Hospitals, University of Toronto

Canadian Society of Surgical Oncology

12th Annual Scientific Meeting, Montreal

Friday, April 1, 2005

Methods

Inclusion Criteria

- Gastric cancer between 1989-2001
- Curative Resection attempt, no distant mets
- Surgical pathology report




Exclusion Criteria

- biopsy only

Mount Sinai Hospital (MSH) Province of Ontario

108 patients
Mount Sinai Hospital
(Dept Pathology Database)
1990-2001

91 patients
across Ontario, age<56
(OCR Database)
1989-1993



The Question of Quality: What do Ontario surgeons strive for?


- n=188 who perform gastric surgery
- # nodes desired
 - mean = 11
 - median = 10 (2-30)
- routine intraop frozen section
 - proximal 53%
 - distal 34%

Helyer, O'Brien, Swallow 2005 unpub


Case #1: Revised Pathology Report

- poorly differentiated adenocarcinoma
- tumour penetrates through muscularis propria into adjacent greater omentum, but not through visceral peritoneum, T2
- proximal and distal margins negative
- 4 of 20 nodes positive, N1

NOW WHAT?



Extent of LND in Intergroup 0116



D2 recommended in protocol
LND assessed from surgical checklist

Hundahl et al, Ann Surg Oncol 2002; 9: 278


D1 Dissection

- ∞ Level 1 nodes (perigastric, stations 1 - 6)
 - right & left cardiac (1 & 2)
 - lesser & greater curve (3 & 4)
 - supra- and infra- pyloric [5 & 6]
- ∞ omentum

D2 Dissection

- ∞ Level 1 nodes (perigastric, stations 1 - 6)
- ∞ Level 2 nodes (intermediate, stations 7 - 9)
 - left gastric (7), common hepatic (8), celiac (9)
- ∞ stations 10 (splenic hilum) and 11 (splenic artery) nodes
- ∞ omental bursa, anterior leaf of mesocolon

THE HOT QUESTION OF TODAY: What is the role of postoperative adjuvant chemoradiation with D2 dissection?



NB: observational study!

Kim et al, Int J Radiation Oncol Biol Phys 2005; 63: 1279

THE HOT QUESTION OF TODAY: What is the role of postoperative adjuvant chemoradiation with D2 dissection?

Korean Protocol: D2

- 5 cycles 5-FU and leucovorin
- 45 Gy RT concurrent from 2nd cycle
- n=291, median f/u 48 mos.
- in-field recurrence rate= 16% (1/3 of all recurrences)
Br J Cancer 2004; 91: 11

Intergroup-0116 RCT of Postoperative Adjuvant Chemoradiation: M & M

- 32% needed change in XRT plan
- 30% couldn't complete Rx
- 1% mortality in C-XRT arm

PMH Protocol for Postoperative Adjuvant Chemoradiation

Eligibility Criteria:

- R0 resection
- < 5 cm into esophagus
- stage 1B - IV, no distant mets
- start 20-90 days post-op

CCO Updated Practice Guideline

" after surgical resection, patients whose tumours have penetrated the MP or involve regional lymph nodes **should be considered** for adjuvant combined chemoradiotherapy "

December, 2002

Management of Resectable Gastric Cancer – Summary

∞ Goals in the resection of localized disease

- R0 resection
- accurate staging
- STG > TG
- D1+ dissection
- adjuvant treatment stage 1B - IV